Use of trastuzumab in the treatment of metastatic endometrial cancer
- 1 May 2006
- journal article
- case report
- Published by BMJ in International Journal of Gynecologic Cancer
- Vol. 16 (3), 1370-1373
- https://doi.org/10.1111/j.1525-1438.2006.00543.x
Abstract
Systemic therapy of metastatic endometrial cancer is relatively ineffective. Response rates to chemotherapy and hormonal therapy in published studies range from 11% to 57%, but most responses are partial and of limited duration. In this case, we present a 76-year-old woman with stage IIIA endometrial adenocarcinoma who was initially treated with surgery and pelvic radiation. She developed multiple pulmonary metastases. She was treated with weekly paclitaxel chemotherapy. Immunostaining revealed that the primary endometrial cancer overexpressed HER-2/neu. Trastuzumab was added to the regimen, and a dramatic partial response was achieved. After a second pulmonary relapse following discontinuation of prior therapy, she was again successfully treated with trastuzumab in combination with paclitaxel and then docetaxel. Therefore, trastuzumab may be a useful adjuvant to taxane-based chemotherapy in some patients with metastatic endometrial cancers that overexpress HER-2/neu.Keywords
This publication has 11 references indexed in Scilit:
- Her-2/neu Overexpression and Amplification in Uterine Papillary Serous CarcinomaJournal of Clinical Oncology, 2004
- Phase III Trial of Doxorubicin Plus Cisplatin With or Without Paclitaxel Plus Filgrastim in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2004
- Evaluation of Monoclonal Humanized Anti-HER2 Antibody, Trastuzumab, in Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma With Overexpression of HER2: A Phase II Trial of the Gynecologic Oncology GroupJournal of Clinical Oncology, 2003
- Molecular and histopathologic predictors of distant failure in endometrial cancerCancer Detection Prevention, 2003
- P53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpressionEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2001
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trialThe Lancet, 2000
- Expression of EGFR, HER-2/neu, P53, and PCNA in Endometrioid, Serous Papillary, and Clear Cell Endometrial AdenocarcinomasGynecologic Oncology, 1994
- HER-2/neu expression: A major prognostic factor in endometrial cancerGynecologic Oncology, 1992
- Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage diseaseAmerican Journal of Obstetrics and Gynecology, 1991